Osimertinib, a third-generation EGFR TKI, showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation advanced NSCLC and a great intracranial penetration with surprisingly high response rates [8, 9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.